PD 173074: Selective FGFR1 Inhibitor for FGFR Signaling Pathway Studies

Executive Summary: PD 173074 is a highly selective small-molecule FGFR tyrosine kinase inhibitor with an IC₅₀ of ~25 nM for FGFR1 in purified enzymatic assays (APExBIO). It exhibits approximately 1000-fold selectivity over kinases such as c-Src and PDGFR, and also inhibits VEGFR2 with an IC₅₀ of 100–200 nM. PD 173074 effectively blocks autophosphorylation and downstream signaling in FGFR-driven models, reducing FGFR-dependent cell proliferation (Bao et al., 2021). The compound is soluble at ≥26.18 mg/mL in DMSO and ≥108.4 mg/mL in ethanol with ultrasonic assistance, but insoluble in water. It is widely used in preclinical studies for target validation, screening, and mechanistic dissection of FGFR signaling.

Biological Rationale

The fibroblast growth factor receptor (FGFR) family comprises four receptor tyrosine kinases (FGFR1–4) that regulate cell proliferation, differentiation, and survival. Dysregulation of FGFR signaling contributes to oncogenesis, especially in head and neck squamous cell carcinoma (HNSCC) and other solid tumors (Bao et al., 2021). DNA methylation patterns in FGFR, FGF, and CCND1 genes are associated with tumorigenesis and may influence response to selective FGFR inhibitors. Targeting FGFR signaling pathways is a validated strategy in cancer research and drug development (see related article—this article extends prior work by including new quantitative benchmarks and epigenetic context).

Mechanism of Action of PD 173074

PD 173074 is a selective FGFR tyrosine kinase inhibitor with a primary mechanism of competitive inhibition at the ATP-binding site of FGFR1. It blocks autophosphorylation of FGFR1, preventing downstream phosphorylation of signaling effectors such as FRS2 and MAPK. The compound also inhibits VEGFR2, though with lower potency. This dual inhibition impedes angiogenesis induced by FGF or VEGF in preclinical animal models. PD 173074 displays minimal activity against unrelated kinases (e.g., c-Src, PDGFR), supporting its utility as a selective probe (APExBIO).

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 kinase activity with an IC₅₀ of ~25 nM in enzymatic assays using purified protein (Bao et al., 2021).
• VEGFR2 is inhibited with an IC₅₀ of 100–200 nM, demonstrating selectivity for FGFR1 (APExBIO, product page).
• No measurable toxicity was observed in Swiss Webster mice administered PD 173074 at 1–2 mg/kg/day intraperitoneally in angiogenesis assays (APExBIO).
• DNA methylation at CCND1 correlates with sensitivity to PD 173074 in HPV-negative HNSCC cell lines (Bao et al., 2021).
• FGFR-dependent cell lines exhibit reduced proliferation when treated with PD 173074, confirming target engagement (see related article—here, we provide updated guidance on product handling and selectivity data).

Applications, Limits & Misconceptions

PD 173074 is widely used in:

• FGFR signaling pathway inhibition studies
• Target validation for FGFR therapeutics development
• Cell proliferation and viability assays in FGFR-dependent lines
• Preclinical angiogenesis inhibition models
• Epigenetic research linking DNA methylation to tyrosine kinase inhibitor sensitivity (see related article—this article clarifies quantitative benchmarks and translational boundaries)

Common Pitfalls or Misconceptions

• PD 173074 is not selective for all FGFR isoforms: it is most potent for FGFR1 and less so for FGFR2–4.
• The compound is insoluble in water—use DMSO or ethanol (with ultrasonic assistance) for stock solutions.
• Long-term storage of solutions is not recommended; stock in DMSO can be kept at <–20°C, but solutions should be used promptly.
• PD 173074 does not reverse established, kinase-independent resistance mechanisms in cancer models.
• Off-target effects may occur at concentrations above 1 μM, especially on VEGFR2.

Workflow Integration & Parameters

• Solubility: Soluble at ≥26.18 mg/mL in DMSO; ≥108.4 mg/mL in ethanol with ultrasound; insoluble in water (APExBIO).
• Storage: Store solid at 4°C and DMSO stock below –20°C; avoid repeated freeze-thaw cycles.
• Dosing: In animal models, 1–2 mg/kg/day i.p. is effective for angiogenesis inhibition.
• In vitro: Working concentrations often range from 10–300 nM for FGFR1 inhibition in cell-based assays (detailed protocol guidance).
• Controls: Include DMSO vehicle controls and, where relevant, independent FGFR inhibitors for benchmarking.

Conclusion & Outlook

PD 173074 from APExBIO (SKU A8253) is a validated, highly selective FGFR1 tyrosine kinase inhibitor that is consistently used in mechanistic, epigenetic, and translational research. Its potency and selectivity profile underpin its status as a gold-standard tool for FGFR signaling pathway inhibition and FGFR-dependent cell proliferation assays. Future studies will further elucidate methylation-driven biomarker selection for FGFR inhibitor response (Bao et al., 2021).

For more information or to order, see the PD 173074 product page at APExBIO.